Animal Studies Support Clinical Findings on EpiCor for Inflammation

April 26, 2012

EpiCor is dried fermentation product from brewer’s yeast (Saccharomyces cerevisiae).

EpiCor developer Embria Health Sciences (Ankeny, IA) says that two new animal studies on EpiCor support findings from previous human studies on the ingredient for immune-health and inflammation control.

EpiCor is dried fermentation product from brewer’s yeast (Saccharomyces cerevisiae).

Researchers from Embria Health Sciences and KGK Synergize (London, ON, Canada) found significant improvements in rats and mice given EpiCor for an extended time period. Rats on EpiCor for 14 days experienced reductions in swelling at all time points, edema severity (50%), and inflammation-enhancing prostaglandin E2 (PGE2) compared to placebo. Mice on EpiCor for four weeks showed significantly reduced arthritis scores and improved antibody responses compared to controls.

Results from the two studies are now available at the journal Evidence-Based Complementary and Alternative Medicine.